Dilon Technologies and ivWatch Selected to Participate in Virginia’s VALET Program

Two-year export program provides resources to support international business expansion to two city of Newport News companies

RICHMOND, VA — The Virginia Economic Development Partnership (VEDP) today announced the acceptance of two City of Newport News companies into its two-year Virginia Leaders in Export Trade (VALET) program: Dilon Technologies, Inc. and ivWatch, LLC. Dilon Technologies delivers clinically useful imaging and intra operative systems appropriate for early disease diagnosis and surgical applications and ivWatch is a leading biosensor technology company that is committed to improving patient safety and the effectiveness of intravenous therapy.

 

The VALET program assists companies in the Commonwealth that are dedicated to expanding international exporting as a growth strategy. To participate, each business must meet both quantitative and qualitative selection criteria. Participating firms are chosen based on their dedication to growing export sales. To date, 348 Virginia companies have been accepted to participate in the VALET program.

“Increasing trade and trade-related jobs in Virginia are among VEDP’s top priorities,” said VEDP Executive Vice President Jason El Koubi. “Executed by our world-class International Trade team, the VALET program has a proven track record of helping Virginia businesses increase their export sales, contributing economic growth and ensuring that Virginia remains competitive in the global marketplace.”

“The VALET program puts participating companies on the fast track to international business growth by connecting them with the necessary tools for successful international sales,” said Stephanie Agee, Vice President of International Trade. “We are excited to welcome these companies into the VALET Program and look forward to working with them over the course of the next two years.”

Currently, the VALET program has 44 companies as participants. The program provides participating companies with export planning services and assistance from a team of experienced international service providers to help meet the companies’ international business goals. These private sector service providers contribute essential expertise to assist companies in executing export plans and include attorneys, web designers, bankers, translators, accountants, and freight forwarders.

The Commonwealth of Virginia exports more than $35 billion in goods and services annually. Exports of Virginia’s products and services to the world are vital to the growth of the Commonwealth, supporting more than 257,000 jobs and generating $2 billion in annual tax revenue. VEDP offers numerous programs to assist Virginia companies with selling into the global marketplace and has a network of international market research consultants covering more than 70 countries around the globe.

 

Dilon Technologies, Inc.

Dilon Technologies delivers clinically useful imaging and intra operative systems appropriate for early disease diagnosis and surgical applications. The Dilon Navigator® Gamma Probe is one of the most widely used gamma probes for cancer surgery in the marketplace. The Dilon CoPilot VL® is an innovative and affordable video laryngoscope designed to make intubation and airway management quick and easy no matter where it is needed. For more information, please visit http://www.dilon.com.

 

ivWatch, LLC

ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

 

Virginia Economic Development Partnership

The Virginia Economic Development Partnership was created by the Virginia General Assembly in 1995 to encourage, stimulate, and support the development and expansion of the economy of the Commonwealth. To accomplish its objectives of promoting economic expansion within the Commonwealth, the Partnership focuses its efforts on business recruitment, expansion and international trade development.

For more information on the VALET Program, visit http://exportvirginia.org/services/programs-grants/

ivWatch Strengthens Management Team with the Appointment of New Executive Members

The Company Announces Three Senior Executives in Finance, Marketing and Sales

Newport News, Va., January 6, 2020 — ivWatch today announced three new additions to its executive management team with the appointments of Teresa (Terry) Blevins as Chief Financial Officer, Erin Wendell as Chief Marketing Officer and Paul Stoddard as Vice President of Sales. These hires will continue to build and strengthen the ivWatch company and its ability to drive growth through financial expertise, strategic marketing initiatives and strong business development.

“We are thrilled to welcome Terry, Erin and Paul, three senior executives with proven track records and vision to the ivWatch team,” said Gary Warren, CEO and President of ivWatch. “Collectively, these leaders will complement our talented team at the company, enrich and advance our global presence, drive awareness in the healthcare industry and to consumers, delivering on our mission to provide safety to our patients by reducing the risks associated with IV infiltration.”

Blevins, Wendell and Stoddard will report directly to Warren and will be based out of the company’s global headquarters in Newport News. As part of the executive team, Blevins will be responsible for the accounting, finance and supply chain functions. Wendell will lead the strategic vision and direction for ivWatch’s global branding and messaging, digital presence, internal and external communications and experiential marketing. Stoddard will oversee the United States sales and clinical divisions, driving growth and new partnerships, revenue and profitability for the ivWatch company.

Terry Blevins, Chief Financial Officer
Blevins joins the company with a strong financial and operations background in large and small businesses from both an internal leadership and external consulting perspective. Blevins has successfully led corporations and their strategic financial planning for over 30 years and she most recently served as the Interim CFO at Psionic Lidar.

Prior to that, she served as CFO of Landmark Media Enterprises, a diverse global holding company of media and technology assets that included The Weather Channel and Norfolk’s metro newspaper, The Virginian Pilot. She has held additional leadership roles in manufacturing with several Fortune 500 companies such as General Electric and Borg Warner.

Blevins is a CPA and has a B.S. in Accounting and a Master’s in Accounting and Information Systems from Virginia Tech in Blacksburg, Va.

Erin Wendell, Chief Marketing Officer
As a member of the executive team, Wendell will lead all aspects of the company’s global brand marketing strategy. Wendell has successfully built global marketing communications, directives, initiatives and experiences for nearly 15 years. She most recently served as the Senior Director of Global Communications at Under Armour. At Under Armour, she played a critical role in growing the communications function from its inception, driving brand awareness, executing entries into global markets, launching major campaigns and products and establishing best in class media and employee communications practices.

Wendell has a B.A. degree in Economics and Business from Randolph-Macon College in Richmond, Va.

Paul Stoddard, Vice President of Sales
Stoddard joins the ivWatch team with a robust background in healthcare sales with over 30 years of experience. Most recently he spent the last 20 years at Phillips Healthcare leading a variety of sales teams in the Ultrasound and Emergency Care & Resuscitation divisions. He comes to ivWatch as a leading dynamic national sales manager with a strong reputation of cultivating new and existing relationships and pioneering brands into their next chapter of growth.

Prior to his tenure at Phillips Healthcare, Stoddard served in a variety of leadership roles at Laerdal Medical Corporation, Pace Tech Inc. and Cardiotronics Inc. Stoddard began his career at First Medical Device Corporation and has a B.S. in Business Administration and Management from York College in York, Pa.

As strategic leaders of ivWatch, each of these executives will partner with all cross functional divisions within the company to grow the business domestically and around the globe.

About ivWatch
ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

ivWatch Headquarter Operations Opens Doors on Aug. 16 for Ribbon-Cutting

Medical device manufacturer welcomes visitors during Tech Center event

NEWPORT NEWS, Va., August 13, 2019 – ivWatch, a biosensor technology company focused on improving patient safety and the effectiveness of intravenous (IV) therapy, will participate in the ribbon-cutting celebration at 10:30 a.m. on August 16, 2019 for the opening of Tech Center Research Park’s Building One. The building, in which ivWatch is an anchor tenant, is the first of 10 buildings planned for the park.

The company designed, assembles, and sells a breakthrough medical device which uses sensor technology to monitor what is happening below the skin and into the tissue during drug/fluid delivery and can detect leakage before the human eye. When the ivWatch system detects a leakage, known as an infiltration, it alerts the medical team to inspect the IV site.

“We have entirely transitioned from being a research and development company to an extensive operation serving health care institutions all over the world,” said Gary Warren, president and CEO of ivWatch. “The strategic build-out in a first-class facility like this provides us with all necessary resources to continue to innovate and make waves in our industry.”

While scouting possible headquarter relocation options, the company required a facility that could adapt to support the year-over-year growth projections of the company and a manufacturing space that would allow the company to build in-house production capabilities.

ivWatch operations are housed within a 25,000 sq. ft. footprint including state-of-the-art manufacturing, R&D and office space, and a large medical setting used to conduct pre- and post-market clinical studies.

“We have assembled an incredible group of people at ivWatch who span various functions and have come to us from incredible career experiences,” said Warren. “I can’t wait to see what type of ecosystem will unfold here as like-minded companies come aboard.”

To learn more about ivWatch, visit www.ivWatch.com.

CONTACT:

  • For all ivWatch media inquiries, please contact Amara Betoney, ivWatch public relations manager, at amara.betoney@ivwatch.com or 757-660-4949.

About ivWatch:
ivWatch, LLC is a medical biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians can leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

ivWatch Positioned for Market Entry with Australian and European Patent Grants

ivWatch leaps to 17 global patents protecting their innovative technologies

NEWPORT NEWS, Va., June 27, 2019 – ivWatch, a biosensor technology company focused on improving patient safety and the effectiveness of intravenous (IV) therapy, expands their foothold in Australia and Europe by securing two patent grants for core product technologies. Additionally, the ivWatch European Patent No. 2830488 announced in October 2018 has been validated in six nations resulting in the following rights:

  • Belgium Patent No. EP2830488
  • Switzerland Patent No. EP2830488
  • Germany Patent No. 602013042197.8
  • France Patent No. EP2830488
  • United Kingdom Patent No. EP2830488
  • Netherlands Patent No. EP2830488

“Whether it be because of central line infection risks, or industry guidance advising against unnecessary placement of peripherally inserted central catheter (PICC) lines, we’re seeing a global shift to the use of more peripheral IVs, or short peripheral catheters, for drug and fluid delivery,” said Gary Warren, president and CEO of ivWatch. “Protecting this technology worldwide ensures medical professionals are certain they are providing highly effective patient monitoring during IV therapy administration.”

The granting of Australian Patent No. 2018211312 is for a technology regarding how an ivWatch sensor head adheres to and is secured on a patient’s skin. These appliances, known as receptacles, can be either independent of the infusion site dressings or integrated within.

The patent bringing the company’s intellectual property (IP) patent portfolio to 17 is European Patent No. 2830487, for mitigating the effects of tissue blood volume changes. This patent describes methods used by ivWatch to extract meaningful signals from biosensors when patients are moving. By mitigating the effects of changing tissue blood volume, the system minimizes “false” alerts. This patent is being validated in several European nations who have shown significant interest in surveillance monitoring for patients receiving medications through peripheral IVs.

View the full patent portfolio at www.ivWatch.com/patents or to learn more about ivWatch, visit www.ivWatch.com.

About ivWatch:
ivWatch, LLC is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians are able to leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Office (855) 489-2824 x7007, Mobile (757) 660-4949

JAVA Study: Evaluating ivWatch Technology in Pediatric IV Sites

Benefits cited include early recognition of infiltration, avoidance of serious injuries, and potential reduction in litigation

NEWPORT NEWS, Va., June 25, 2019 – A new study in the peer-reviewed Journal of the Association for Vascular Access (JAVA) examines several important metrics that describe the performance of the ivWatch Model 400 at a leading children’s hospital in Ohio. The key finding of the pilot study was the device detected a peripheral IV infiltration 80 percent of the time before the clinician detected the leakage event.

Data was collected on 156 patients where the ivWatch Model 400 was incorporated into IV therapy but did not notify clinicians of infiltration, and then compared to data on 57 patients where the ivWatch Model 400 notified clinicians via audible and visual alerts about infiltration events. This allowed investigators to analyze how the ivWatch Model 400 compared to clinicians’ assessments in the early detection of IV infiltration. Success was measured by the frequency of infiltration events and how often the device issued notifications.

The study, which appears in the Summer 2019 issue of JAVA, showed that on average the device issued a notification signaling a possible infiltration (Yellow Check IV) 32.3 hours prior to a clinician detecting it, while a notification signaling a probable infiltration (Red Check IV) was issued an average of 29.8 hours prior to clinician detection. It was also concluded by the authors of the study at Cincinnati Children’s Hospital, “technology that provides early detection of IV infiltrations may be advantageous for the patient, clinician, and institution.”

This pilot study was undertaken in part because of the medical center’s commitment to patient safety including efforts to reduce severe and moderate peripheral IV infiltration and extravasation occurrences. The results underline the practice of using an additional intervention in conjunction with following industry recommendations of IV site assessment to promote the earliest possible identification of this common complication of IV therapy.

The study titled “The Use of Optical Detection for Continuous Monitoring of Pediatric IV Sites” was authored by Darcy Doellman, MSN, RN, CRNI, VA-BC and Sylvia Rineair, MSHA, BSN, RN, VA-BC. The abstract can be viewed at https://www.avajournal.com/doi/abs/10.2309/j.java.2019.002.003, and the article citation is:

  • Darcy Doellman and Sylvia Rineair (2019) The Use of Optical Detection for Continuous Monitoring of Pediatric IV Sites. Journal of the Association for Vascular Access: Summer 2019, Vol. 24, No. 2, pp. 44-47.

To learn more about ivWatch, visit www.ivWatch.com.

About ivWatch:
ivWatch, LLC is a biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is pioneering the use of optical sensors to detect adverse IV events early to minimize the risk of injury caused by infiltrations and extravasations. By using this technology, clinicians are able to leverage continuous monitoring to help identify infiltrations as early as possible. Our innovative monitored IV solutions are backed by decades of clinical research and device development. To learn more, follow us on Twitter @ivWatch or Facebook @ivWatchLLC, or visit www.ivwatch.com.

ivWatch is pleased to sponsor the work of myIV.com, an online resource dedicated to empowering visitors with information on all things IV, simplified.

MEDIA CONTACT: Amara Betoney, amara.betoney@ivwatch.com, Office (855) 489-2824 x7007, Mobile (757) 660-4949


In the News: Companies Combating IV Infiltrations

Patient Safety & Quality Healthcare (PSQH) discussed IV infiltration and it’s potential for life-threatening consequences in a recent article. The piece, “Companies Work to Help Combat IV Infiltrations” includes commentary from ivWatch President and CEO, Gary Warren, and cites the ivWatch Model 400 as a clinician partner helping to deliver improved patient care with constant monitoring of the IV site. Read the full article here.

ivWatch Logo White

Download Our Whitepaper

Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.

[fc id='6'][/fc]

You have Successfully Subscribed!

Pin It on Pinterest